



# VACCINATIONS FOR ADULT HORSES

**\*\*ALL VACCINATION PROGRAMS SHOULD BE DEVELOPED IN CONSULTATION WITH A LICENSED VETERINARIAN\*\***

**CORE VACCINATIONS protect against diseases that are endemic to a region, are virulent/highly contagious, pose a risk of severe disease, those having potential public health significance, and/or are required by law. Core vaccines have clearly demonstrable efficacy and safety, with a high enough level of patient benefit and low enough level of risk to justify their use in all equids.**

	Broodmares	Other Adult Horses (> 1 year of age) <i>previously vaccinated against the disease indicated</i>	Other Adult Horses (> 1 year of age) <i>unvaccinated</i> <i>or</i> <i>lacking vaccination history</i>	
DISEASE				COMMENTS
<b>Tetanus</b>	<p><i>Previously vaccinated:</i> Annual, 4 - 6 weeks pre-partum</p> <p><i>Previously unvaccinated or having unknown vaccination history:</i> <b>2-dose series</b> 2<sup>nd</sup> dose 4-6 weeks after 1<sup>st</sup> dose. Revaccinate 4-6 weeks pre-partum</p>	Annual	<p><b>2-dose series</b> 2<sup>nd</sup> dose 4 - 6 weeks after 1<sup>st</sup> dose. Annual revaccination</p>	Booster at time of penetrating injury or prior to surgery if last dose was administered over 6 months previously.
<b>Eastern / Western Equine Encephalomyelitis (EEE/WEE)</b>	<p><i>Previously vaccinated:</i> Annual, 4 - 6 weeks pre-partum</p> <p><i>Previously unvaccinated or having unknown vaccination history:</i> <b>2-dose series</b> 2<sup>nd</sup> dose 4 weeks after 1<sup>st</sup> dose. Revaccinate 4-6 weeks pre-partum.</p>	Annual – spring, prior to onset of vector season.	<p><b>2-dose series</b> 2<sup>nd</sup> dose 4 - 6 weeks after 1<sup>st</sup> dose.</p> <p>Revaccinate prior to the onset of the next vector season.</p>	<p>Consider 6-month revaccination interval for:</p> <ol style="list-style-type: none"> <li>1) Horses residing in endemic areas</li> <li>2) Immunocompromised horses</li> </ol>

<p><b>West Nile Virus (WNV)</b></p>	<p><i>Previously vaccinated:</i> Annual, 4 - 6 weeks pre-partum</p> <p><i>Unvaccinated or lacking vaccination history:</i> It is preferable to vaccinate naïve mares when open.</p> <p>In areas of high risk, initiate primary series as described for unvaccinated, adult horses.</p>	<p>Annual – spring, prior to onset of vector season</p>	<p><u><i>Inactivated whole virus vaccine:</i></u> 2-dose series 2<sup>nd</sup> dose 4 - 6 weeks after 1<sup>st</sup> dose. Revaccinate prior to the onset of the next vector season.</p> <p><u><i>Recombinant canary pox vaccine:</i></u> 2-dose series 2<sup>nd</sup> dose 4 - 6 weeks after 1<sup>st</sup> dose. Revaccinate prior to the onset of the next vector season.</p> <p><u><i>Inactivated flavivirus chimera vaccine:</i></u> 2-dose series 2<sup>nd</sup> dose 3 - 4 weeks after 1<sup>st</sup> dose. Revaccinate prior to the onset of the next vector season.</p>	<p>When using the inactivated or the recombinant product, consider 6-month revaccination interval for:</p> <ol style="list-style-type: none"> <li>1) Horses residing in endemic areas</li> <li>2) Juvenile (&lt;5 yrs of age)</li> <li>3) Geriatric horses (&gt; 15 yrs of age)</li> <li>4) Immunocompromised horses</li> </ol>
<p><b>Rabies</b></p>	<p>Annual, 4 - 6 weeks pre-partum OR Prior to breeding*</p>	<p>Annual</p>	<p>Single dose Annual revaccination</p>	<p>*Due to the relatively long duration of immunity, this vaccine may be given post-foaling but prior to breeding and thus reduce the number of vaccines given to a mare pre-partum.</p>

**RISK-BASED VACCINES** are selected for use based on risk assessment\*\* performed by, or in consultation with, a licensed veterinarian. Use of these vaccines may vary between individuals, populations, and/or geographic regions.

Note: Vaccines are listed in this table in alphabetical order, not in order of priority for use.

\*\*Refer to “Principles of Vaccination” in main document for criteria used in performing risk assessment.

	Broodmares	Other Adult Horses (> 1 year of age) <i>previously vaccinated against the disease indicated</i>	Other Adult Horses (> 1 year of age) <i>unvaccinated or lacking vaccination history</i>	
DISEASE				COMMENTS
<b>Anthrax</b>	Not recommended during gestation	Annual	<b>2-dose series</b> 2 <sup>nd</sup> dose 3-4 weeks after 1 <sup>st</sup> dose. Annual revaccination.	Do not administer concurrently with antibiotics.  Use caution during storage, handling and administration. Consult a physician immediately if human exposure to vaccine occurs by accidental injection, ingestion, or otherwise through the conjunctiva or broken skin.
<b>Botulism</b>	<i>Previously vaccinated:</i> Annual, 4 - 6 weeks pre-partum  <i>Previously unvaccinated or having unknown vaccination history:</i> <b>3-dose series</b> 1 <sup>st</sup> dose at 8 months gestation. 2 <sup>nd</sup> dose 4 weeks after 1 <sup>st</sup> dose 3 <sup>rd</sup> dose 4 weeks after 2 <sup>nd</sup> dose	Annual	<b>3-dose series</b> 2 <sup>nd</sup> dose 4 weeks after 1 <sup>st</sup> dose 3 <sup>rd</sup> dose 4 weeks after 2 <sup>nd</sup> dose  Annual revaccination	

<p align="center"><b>Equine Herpesvirus (EHV)</b></p>	<p><b>3-dose series</b> with product labeled for protection against EHV abortion</p> <p>Give at 5, 7 and 9 months of gestation</p>	<p>Annual (see comments)</p>	<p><b>3-dose series</b>  <b>2<sup>nd</sup></b> dose 4-6 weeks after 1<sup>st</sup> dose  <b>3<sup>rd</sup></b> dose 4-6 weeks after 2<sup>nd</sup> dose</p>	<p>Consider 6-month revaccination interval for:</p> <ol style="list-style-type: none"> <li>1) Horses less than 5 years of age</li> <li>2) Horses on breeding farms or in contact with pregnant mares</li> <li>3) Performance or show horses at high risk</li> </ol>
<p align="center"><b>Equine Viral Arteritis (EVA)</b></p>	<p>Not recommended unless high risk</p>	<p>Annual</p> <p><i>Stallions, teasers:</i> Vaccinate 2 - 4 weeks before breeding season</p> <p><i>Mares:</i> Vaccinate when open</p>	<p><b>Single dose</b> (See comments)</p>	<p><b><u>Prior to initial vaccination, intact males and any horses potentially intended for export should undergo serologic testing</u></b> and be confirmed negative for antibodies to EAV. Testing should be performed shortly prior to, or preferably at, the time of vaccination.</p>
<p align="center"><b>Influenza</b></p>	<p><i>Previously vaccinated:</i>  <u>Inactivated vaccine:</u>  Semi-annual with one dose administered 4 - 6 weeks pre-partum</p> <p><u>Canary pox vector vaccine:</u>  Semi-annual with one dose administered 4 - 6 weeks pre-partum</p> <p><i>Previously unvaccinated or having unknown vaccination history:</i>  <u>Inactivated vaccine:</u> 3-dose series  <b>2<sup>nd</sup></b> dose 4 - 6 weeks after 1<sup>st</sup> dose  <b>3<sup>rd</sup></b> dose 4 - 6 weeks pre-partum</p> <p><u>Canary pox vector vaccine:</u>  2-dose series  <b>2<sup>nd</sup></b> dose 4 - 6 weeks after 1<sup>st</sup> dose but no later than 4 weeks pre-partum</p>	<p>Horses with ongoing risk of exposure: Semi-annual</p> <p>Horses at low risk of exposure: Annual.</p>	<p><u>Modified live vaccine:</u>  Single dose administered intranasally. Revaccinate semi-annually to annually</p> <p><u>Inactivated vaccine:</u> 3-dose series  <b>2<sup>nd</sup></b> dose 4 - 6 weeks after 1<sup>st</sup> dose.  <b>3<sup>rd</sup></b> dose 3 - 6 months after 2<sup>nd</sup> dose.  Revaccinate semi-annually to annually</p> <p><u>Canary pox vector vaccine:</u> 2-dose series  <b>2<sup>nd</sup></b> dose 4 - 6 weeks after 1<sup>st</sup> dose.  Revaccinate semi-annually</p>	

<p><b>Leptospirosis</b></p>	<p>Safe for use in pregnant mares</p> <p><i>Previously unvaccinated or having unknown vaccination history:</i> 2 Initial doses 3-4 weeks apart</p> <p><i>Previously vaccinated:</i> Annual revaccination</p>	<p>Annual</p>	<p>2 initial doses 3-4 weeks apart</p> <p>Annual revaccination</p>	<p>Field safety testing has demonstrated this product is safe for use in pregnant mares</p>
<p><b>Potomac Horse Fever (PHF)</b></p>	<p><i>Previously vaccinated:</i> Semi-annual, with one dose given 4 - 6 weeks pre-partum</p> <p><i>Previously unvaccinated or having unknown vaccination history:</i> <b>2-dose series</b> 1<sup>st</sup> dose 7-9 weeks pre-partum 2<sup>nd</sup> dose 4-6 weeks pre-partum</p>	<p>Semi-annual to annual</p>	<p><b>2-dose series</b> 2<sup>nd</sup> dose 3-4 weeks after 1<sup>st</sup> dose Semi-annual or annual booster</p>	<p>A revaccination interval of 3 - 4 months may be considered in endemic areas when disease risk is high.</p>
<p><b>Rotavirus</b></p>	<p><b>3-dose series</b> 1<sup>st</sup> dose at 8 months gestation. 2<sup>nd</sup> and 3<sup>rd</sup> doses at 4-week intervals thereafter</p>	<p>Not applicable</p>	<p>Not applicable</p>	
<p><b>Snake Bite</b></p>	<p>Please see guidelines for additional information</p>	<p>Please see guidelines for additional information</p>	<p>Please see guidelines for additional information</p>	
<p><b>Strangles</b> <i>Streptococcus equi</i></p>	<p><i>Previously vaccinated:</i></p> <p><u><i>Killed vaccine containing M-protein:</i></u></p> <p>Semi-annual with one dose given 4 - 6 weeks pre-partum</p> <p><i>Previously unvaccinated or having unknown vaccination history:</i></p> <p><u><i>Killed vaccine containing M-protein:</i></u> <b>3-dose series</b> 2<sup>nd</sup> dose 2 - 4 weeks after 1<sup>st</sup> dose</p>	<p>Semi-annual to annual</p>	<p><u><i>Killed vaccine containing M-protein:</i></u> <b>2-3 dose series</b> 2<sup>nd</sup> dose 2 - 4 weeks after 1<sup>st</sup> dose 3<sup>rd</sup> dose (where recommended by manufacturer) 2 - 4 weeks after 2<sup>nd</sup> dose Revaccinate semi-annually</p> <p><u><i>Modified live vaccine:</i></u> <b>2-dose series administered intranasally</b> 2<sup>nd</sup> dose 3 weeks after 1<sup>st</sup> dose Revaccinate semi-annually to annually</p>	<p>Vaccination is <b>not</b> recommended as a strategy in outbreak mitigation.</p>

	3 <sup>rd</sup> dose 4 - 6 weeks pre-partum			
--	---------------------------------------------	--	--	--

*Vaccinations for Adult Horses developed by the American Association of Equine Practitioners Infectious Disease Committee, 2008 and updated by the AAEP Biological & Therapeutic Agents Committee in 2012 and again updated by an AAEP Vaccination Guidelines Review Task Force in 2015.*